Saudi Arabia is the largest pharmaceutical market in the Middle East. Primary research with Saudi physicians — integrated with hospital sales and consumption data — is the foundation of effective launch planning, brand tracking, market access strategy, and real-world evidence generation in the Kingdom.
BioNixus has been conducting physician surveys and integrating them with hospital-level and pharmacy-sourced data across Saudi Arabia since 2012, from offices in London and Cairo. This guide covers everything a pharma or biotech research team needs to know before commissioning HCP research in KSA.
Saudi Arabia has approximately 82,000 licensed physicians across public and private sectors, with around 30,000 in specialist roles. Prescribing is highly institutional — concentrated within distinct hospital networks that operate independently of each other:
| Network | Characteristics |
|---|---|
| MOH hospital network | 260+ hospitals; largest employer; follows NUPCO formulary |
| National Guard Health Affairs (NGHA) | Parallel system; independent formulary; separate procurement |
| KFSH&RC | Dominant tertiary centre; highest KOL density; sets protocol standards |
| Ministry of Defence Medical Services | Third parallel system; distinct access requirements |
| Private hospital sector | Growing fastest; insurance-driven; premium-price friendly |
Understanding which network a physician works within is essential for survey design — prescribing authority, formulary access, and treatment decision-making differ materially across these networks.
BioNixus's physician survey programmes are designed to integrate with hospital sales data and consumption analytics — not operate in isolation. This integration is what separates actionable commercial intelligence from standalone survey output.
BioNixus first analyses hospital-level and pharmacy-sourced consumption data for the relevant therapy area across Saudi Arabia. This identifies the highest-volume hospital accounts and departments — the institutions where prescribing decisions have the greatest commercial impact.
Physician survey quotas are then stratified to ensure adequate representation from these high-volume institutions. The survey findings — what physicians say they prescribe and why — are then analysed in the context of what consumption data shows is actually being prescribed.
The combined output answers the question that neither data source can answer alone: not just what is being prescribed, but why — and what would change prescribing behaviour.
This integrated methodology is particularly valuable for:
Language: Arabic-language surveys consistently produce higher response rates, richer qualitative responses, and more accurate reflection of real clinical practice. BioNixus conducts all Saudi Arabia physician surveys with certified medical Arabic translation, reviewed by clinically qualified translators for therapy area terminology precision. Bilingual design — Arabic primary, English reference — is our standard for quantitative fieldwork.
Recruitment: BioNixus maintains a recruited, verified panel of Saudi physicians across specialties, with identity verification against Saudi Commission for Health Specialties (SCHS) registration, specialty and institutional affiliation confirmation, and ongoing panel relationship management. The Saudi medical community is not reachable through generic consumer research panels.
All BioNixus physician surveys in Saudi Arabia comply with:
Incentive Structure: Professional honoraria of SAR 150–400 per completed interview, calibrated to survey length and specialty, in line with SCHS guidance. Digital gift card formats are preferred for compliance documentation.
| Specialty | KSA Specialist Pool | Realistic Survey Sample |
|---|---|---|
| General Practitioners | ~18,000 | 200–400 |
| Endocrinologists | ~600 | 60–100 |
| Cardiologists | ~1,200 | 100–200 |
| Pulmonologists | ~400 | 60–90 |
| Neurologists | ~500 | 50–100 |
| Rheumatologists | ~350 | 50–80 |
| Oncologists | ~200 | 40–80 |
| Haematologists | ~150 | 30–60 |
For ultra-specialised therapy areas, qualitative depth interviews with 15–25 physicians deliver more actionable insight than pushing for quantitative sample sizes the market cannot support.
Completion rates drop significantly beyond this threshold. Split complex research topics into a quantitative survey and a separate qualitative follow-up.
Set quotas by hospital network — MOH, NGHA, private — and by region — Riyadh, Jeddah, Mecca, Eastern Province. Without institutional stratification, your data will over-represent whichever physician type is easiest to recruit.
Cross-reference trade names with SFDA registration names — these occasionally differ from European or US registered names.
Questions about NUPCO decisions or MOH policy should focus on clinical reasoning. Saudi physicians engage more openly when questions reflect genuine clinical interest rather than commercial intelligence gathering.
| Phase | Duration |
|---|---|
| Questionnaire design and Arabic translation | 1–2 weeks |
| Consumption data pre-analysis and quota setting | 1 week |
| IRB / ethics submission (if required) | 2–6 weeks |
| Pilot fieldwork (n=10) | 1 week |
| Main fieldwork | 2–4 weeks |
| Data integration, cleaning, and analysis | 1–2 weeks |
| Report and presentation | 1 week |
| Total — without IRB | 6–10 weeks |
| Total — with IRB | 9–16 weeks |
Free feasibility review including consumption data pre-analysis. Response within 24 hours.
BioNixus has delivered integrated HCP research and data programmes across MENA since 2012.